Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

In May, Hims & Hers started prescribing compounded semaglutide, the active ingredient in Novo Nordisk's blockbuster GLP-1 medications Ozempic and Wegovy. Hims & Hers Health shares plunged 18% in ...

Hims & Hers turned in tremendous revenue and profitability growth in the fourth quarter. The company also issued very robust guidance. However, it will stop selling semaglutide-based weight-loss ...

As the telehealth industry has grown, Hers has followed suit. It has expanded its offerings to include weight loss, focusing on prescription medications, including its own compounded semaglutide ...

An ad for compounded versions of weight-loss drug semaglutide by telehealth company Hims & Hers has attracted the ire of a pharmaceutical trade organisation that calls the campaign "nothing short ...

Researchers suggest the 20% reduction in nonfatal heart attacks was the primary driver of this benefit for patients with type ...

The source of investor bearishness in previous days was Hims & Hers' announcement on Monday that it might halt sales of a highly popular product -- compound versions of semaglutide, the white-hot ...

Hims & Hers Health (HIMS) stock enjoyed a 10% jump in price last week on news that the company plans to continue offering ...

However, the stock gave back a lot of gains after semaglutide, the active ingredient in GLP-1 weight loss drug Ozempic, was taken off the Food & Drug Administration's shortage list. Hims & Hers ...